Trials / Completed
CompletedNCT02217488
Single Ascending Dose Tolerability Study of DG3173
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Aspireo Pharmaceuticals Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This clinical trial investigated the safety, tolerability and pharmacokinetic profile of DG3173 in a double-blind, randomized, placebo-controlled, single dose escalation Phase 1 study involving 72 healthy volunteers. Individuals received up to 2000 µg of DG3173 via single dose subcutaneous injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DG3173 | |
| DRUG | Placebo |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2008-09-01
- First posted
- 2014-08-15
- Last updated
- 2014-08-15
Source: ClinicalTrials.gov record NCT02217488. Inclusion in this directory is not an endorsement.